Onureg, a maintenance therapy for acute myeloid leukemia, is on its way to entering insurance coverage. As a result of the coverage, Onureg is scheduled to be presented to the Pharmaceutical Reimbursement Evaluation Committee of the Health Insurance Review and Assessment Service on the 6th. It has been about four months since the passage of the Cancer Diseases Review Committee in December of last year. On March 23, 2022, this drug was approved for maintenance therapy in adult patients with acute myeloid leukemia who achieved CR or CRi after induction therapy, with or without consolidation therapy, and for whom HSCT is unsuitable.

As the first and only treatment option that clinically extended th